Ruiz-Pérez NJ, Arriaga-Alba M, Ocharán-Hernández ME, Sánchez-Navarrete J, Pérez-Cruz E, Montes-Vera MR, Rodríguez-Wong U, Cruz-Rico J

Language: Spanish
References: 10
Page: 28-33
PDF size: 136.53 Kb.

ABSTRACT

Fungal infections of skin and mucous membranes, as well as systemic, are now a public health problem in developed countries. The growing number of these infections and resistance to conventional treatments, among other factors, have resulted in the continuing evolution of antifungal agents, since the middle of last century to date. In 1990 were introduced triazoles, fluconazole specifically. The aim of this study was to review some aspects of this antifungal agent pharmacokinetic: mechanism of action, drug interactions, biological activity, routes of administration and hepatotoxic effects in children.

REFERENCES

1. Campbell BC, Chan KL, Kim JH. Chemosensitization as a means to augment commercial antifungal agents. Front Microbiol 2012; 3: 79.

2. Burger-Kentischer, Finkelmeier, Keller, Bauer, Eickhoff, Kleymann, Abu, et al. A screening assay based on hostpathogen interaction models identifies a set of novel antifungal benzimidazole derivatives. Antimicrob Agentes Chemother 2011; 55: 4879-81.

3. Fica CA. Tratamiento de infecciones fúngicas sistémicas. Primera parte: fluconazol, itraconazol y voriconazol. Rev Chil Infect 2004; 21(1): 26-38.

4. Wakeham K, Parkes-Ratanshi R, Watson V, Ggayi AB, Khoo S, Lalloo DG. Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. J Antimicrob Chemother 2010; 65(2): 316-9.

5. Yamazaki H, Nakamoto M, Shimizu M, Murayama N, Niwa T. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br J Clin Pharmacology 2010; 69(6): 593-7.

6. Chen CK, Leung SS, Guilbert C, Jacobson MP, McKerrow JH, Podust LM. Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl Trop Dis 2010; 4(4): e651.

7. Salerno C, Carlucci AM, Bregni C. Study of in vitro drug release and percutaneous absorption of fluconazole from topical dosage forms. AAPS Pharm Sci Tech 2010; 11(2): 986-93.

8. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010; 23(4): 858-83.

9. Piper L, Smith PB, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G, Hope WW, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Disease J 2011; 30(5): 375-8.

10. Wade KC, Benjamin DK Jr., Kaufman DA, Ward RM, Smith PB, Jayaraman B, Adamson PC, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 2009; 28(8): 717-23.